Early access
Sign in
Enrolling by invitationNo phase

The DiNAM-EoE-C Study: Esophageal Distensibility and Novel Assessment of Motility in Eosinophilic Esophagitis

Key facts

Who runs it
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
25 people, planned
Started
1 May 2026
Expected to end
1 Aug 2027
Type of study
Observational
Record updated
29 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Confirmed diagnosis of eosinophilic esophagitis in histological remission (<15 eosinophils/HPF)
  • Persistent symptoms (e.g., dysphagia, food impaction, chest pain) despite medical or dietary therapy
  • Stable EoE therapy throughout the study duration (proton pump inhibitors, budesonide, dupilumab, dietary therapies)
  • Signed informed consent

Who cannot take part

  • Previous diagnosis of severe erosive esophagitis (Los Angeles grade C or higher)
  • Previous diagnosis of esophagogastric junction outflow disorders (e.g., achalasia)
  • Systemic diseases involving the esophagus (e.g., scleroderma)
  • Use or initiation during the study of immunosuppressive or biological drugs, or medications affecting esophageal motility (opioids, nitrates, calcium channel blockers)
  • Presence of R3 and/or S1 (according to EREFS)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Eosinophilic esophagitis is a chronic immune-mediated disease that may progress to fibrostenotic remodeling, leading to symptoms such as dysphagia, chest pain, and food impaction. Although current therapies aim to achieve inflammatory control and prevent fibrosis, some patients remain symptomatic despite endoscopic and histologic remission. In this subgroup, symptoms may reflect reduced esophageal distensibility, motility abnormalities, or altered symptom perception related to hypervigilance. This study aims to evaluate symptomatic EoE patients in histologic remission by assessing esophageal distensibility with FLIP before and after endoscopic dilation, investigating motility abnormalities with HRM, and exploring the role of hypervigilance in clinical outcomes.

The group in the trial

  • EoE Patients in Histologic Remission with persistent symptoms

    EoE Patients in Histologic Remission with persistent symptoms without strictures underwent dilation and FLIP

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The DiNAM-EoE-C Study: Esophageal Distensibility and Novel Assessment of Motility in a Eosinophilic Esophagitis Cohort With Residual Symptoms Despite Histological Remission
Record updated
29 July 2026